Publications
Detailed Information
Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: A double-blind, randomized, placebo-controlled, multicenter trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Byung In | - |
dc.contributor.author | Yi, Sangdoe | - |
dc.contributor.author | Hong, Seung Bong | - |
dc.contributor.author | Kim, Myeong-Kyu | - |
dc.contributor.author | Lee, Sang Kun | - |
dc.contributor.author | Kim, Jae Moon | - |
dc.contributor.author | Heo, Kyoung | - |
dc.contributor.author | Leon, Teresa | - |
dc.contributor.author | Lowe, Wing | - |
dc.contributor.author | Song, Hong Ki | - |
dc.contributor.author | Shin, Dong-Jin | - |
dc.contributor.author | Lee, Sang Ahm | - |
dc.date.accessioned | 2012-06-18T06:04:13Z | - |
dc.date.available | 2012-06-18T06:04:13Z | - |
dc.date.issued | 2009-03 | - |
dc.identifier.citation | EPILEPSIA; Vol.50 3; 464-474 | ko_KR |
dc.identifier.issn | 0013-9580 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77126 | - |
dc.description.abstract | Purpose: To evaluate the efficacy and safety of pregabalin (PGB) as adjunctive therapy, using a flexible-dosing schedule in Korean patients with refractory partial-onset seizures. Methods: This randomized, double-blind (DB), placebo-controlled trial consists of a 6-week baseline, a 12-week DB treatment, and a 1-week taper phase. Patients having recurrent partial seizures (4 seizures during baseline phase) under adequate pharmacotherapy were recruited to be randomized to PGB or placebo (PLC) in a 2 to 1 ratio. Starting dose was 150 mg/day, increased every 2 weeks by 150-mg/day increments up to maximum dose of 600 mg/day. The primary efficacy parameter was response ratio (RRatio) for all partial seizures. Results: A total of 178 patients (119 in PGB, 59 in PLC) were assigned to the study. Median daily doses of PGB and PLC were 367 and 420 mg/day, respectively. RRatio least squares (LS) mean was) -35.8 in the PGB group and) -23.2 in the PLC group, with estimated difference in RRatios being) -12.6 [95% confidence interval (CI):) 22.7 to) -2.5, p = 0.015] in the intent-to-treat (ITT) population. Analysis of secondary efficacy measures showed a general trend favoring PGB over PLC. Seventy-seven patients (64.7%) in the PGB group and 18 patients (30.5%) in the PLC group developed adverse events (AEs) related to the study drug. Seven patients (5.9%) in the PGB group discontinued the study prematurely because of AEs. In the post hoc analysis, a significant weight gain (>= 7% of baseline body weight) was found in 24.8% of patients taking PGB, which was more frequent in patients with a lower body mass index (BMI <= 20). Discussion: PGB was effective and easily tolerable as add-on treatment in an Asian population with refractory partial-onset seizures. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.subject | Pregabalin | ko_KR |
dc.subject | Response ratio | ko_KR |
dc.subject | Flexible-dosing schedule | ko_KR |
dc.subject | Add-on therapy | ko_KR |
dc.subject | Tolerability | ko_KR |
dc.title | Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: A double-blind, randomized, placebo-controlled, multicenter trial | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이병인 | - |
dc.contributor.AlternativeAuthor | 이상도 | - |
dc.contributor.AlternativeAuthor | 홍승봉 | - |
dc.contributor.AlternativeAuthor | 김명규 | - |
dc.contributor.AlternativeAuthor | 이상암 | - |
dc.contributor.AlternativeAuthor | 이상건 | - |
dc.contributor.AlternativeAuthor | 신동진 | - |
dc.contributor.AlternativeAuthor | 김재문 | - |
dc.contributor.AlternativeAuthor | 송홍기 | - |
dc.contributor.AlternativeAuthor | 허경 | - |
dc.identifier.doi | 10.1111/j.1528-1167.2008.01954.x | - |
dc.citation.journaltitle | EPILEPSIA | - |
dc.description.citedreference | BEYDOUN A, 2008, EXPERT REV NEUROTHER, V8, P1013 | - |
dc.description.citedreference | Taylor CP, 2007, EPILEPSY RES, V73, P137, DOI 10.1016/j.eplepsyres.2006.09.008 | - |
dc.description.citedreference | Elger CE, 2005, EPILEPSIA, V46, P1926 | - |
dc.description.citedreference | Ryvlin P, 2005, EUR J NEUROL, V12, P12 | - |
dc.description.citedreference | Brodie MJ, 2005, EPILEPSIA, V46, P1407 | - |
dc.description.citedreference | Zareba G, 2005, DRUGS TODAY, V41, P509, DOI 10.1358/dot.2005.41.8.910482 | - |
dc.description.citedreference | Beydoun A, 2005, NEUROLOGY, V64, P475 | - |
dc.description.citedreference | Ben-Menachem E, 2004, EPILEPSIA, V45, P13 | - |
dc.description.citedreference | Brodie MJ, 2004, EPILEPSIA, V45, P19 | - |
dc.description.citedreference | Arroyo S, 2004, EPILEPSIA, V45, P20 | - |
dc.description.citedreference | HUCKLE R, 2004, CURR OPIN INVEST DR, V5, P82 | - |
dc.description.citedreference | Fehrenbacher JC, 2003, PAIN, V105, P133, DOI 10.1016/S0304-3959(03)00173-8 | - |
dc.description.citedreference | Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7 | - |
dc.description.citedreference | French JA, 2003, NEUROLOGY, V60, P1631 | - |
dc.description.citedreference | Lauria-Horner BA, 2003, EXPERT OPIN INV DRUG, V12, P663 | - |
dc.description.citedreference | Burneo JG, 2002, EPILEPSY BEHAV, V3, P532 | - |
dc.description.citedreference | Dooley DJ, 2002, SYNAPSE, V45, P171, DOI 10.1002/syn.10094 | - |
dc.description.citedreference | Birbeck GL, 2002, EPILEPSIA, V43, P535 | - |
dc.description.citedreference | Fink K, 2002, NEUROPHARMACOLOGY, V42, P229 | - |
dc.description.citedreference | BENMENACHEM E, 2002, ANTIEPILEPTIC DRUGS, P901 | - |
dc.description.citedreference | Dooley DJ, 2000, J PHARMACOL EXP THER, V295, P1086 | - |
dc.description.citedreference | Bockbrader HN, 2000, NEUROLOGY, V54, pA421 | - |
dc.description.citedreference | Cramer JA, 1999, EPILEPSIA, V40, P590 | - |
dc.description.citedreference | WILLIAMSON J, 1997, EPILIPSIA, V38, P29 | - |
dc.description.citedreference | BANCAUD J, 1981, EPILEPSIA, V22, P489 | - |
dc.description.tc | 8 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.